Immune-mediated inflammatory myopathies (IMIMs) are rare disorders that encompass multiple subtypes including dermatomyositis, immune-mediated necrotizing myopathy or necrotizing autoimmune myopathy (NAM), and alpha-synthetase syndrome. While their pathogenesis is unclear, research is rapidly uncovering novel targets and disease markers. The management of these disorders is evolving as autoantibody markers are linked to patient comorbidities, as patient heterogeneity increasingly comes into focus, and as novel drugs progress through the pipeline. Potential line extensions for branded biologics are also nearing final stages of the pipeline. With an increasingly crowded pipeline and a limited number of patients and multiple treating physicians, which therapies are poised to dominate these niche markets?
· What is the diagnosed prevalence of dermatomyositis, of immune-mediated necrotizing myopathy, and of the alpha-synthetase syndrome?
· How are each of the subpopulations treated today?
· What are the key areas of unmet need and opportunity in the management of immune-mediated inflammatory myopathies?
· What is the potential impact of new launches and how will these therapies affect future opportunity in the different subtypes of immune-mediated inflammatory myopathies?
· What are the key drivers and limiters of the market today and in the future?
Executive Insights provides indication-specific market intelligence with world-class epidemiology, keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.